Summit Therapeutics Inc. — Director's Dealing 2022

Dec 9, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2022-12-06

Reporting Person: DUGGAN ROBERT W (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-06	Common Stock	J	9346434	—	Acquired	171879226	Direct

Footnotes

F1: 9,346,434 shares of Common Stock were issued to the Reporting Person as payment of interest in connection with a Note Purchase Agreement, dated December 6, 2022, by and among the Issuer, the Reporting Person and Dr. Maky Zanganeh. The determination of the number of shares of Common Stock to be issued to the Reporting Person was based on a per share price of $0.79.